<DOC>
	<DOCNO>NCT02263326</DOCNO>
	<brief_summary>HIV-1 infected subject CD4 nadir &gt; 200 cells/mm3 , history virologic failure plasma HIV RNA &lt; 50 copies/mL least 48 week United States Department Health Human Services ( DHHS ) recommend alternative three-drug antiretroviral regimen randomize dolutegravir ( DTG ) plus lamivudine ( Arm 1 ) continuation current regimen ( Arm 2 ) 48 week . The primary endpoint virologic failure define confirmed plasma HIV-1 RNA &gt; 50 copies/mL Week 24</brief_summary>
	<brief_title>Dolutegravir Antiretroviral Strategy Promote Improvement Reduce Drug Exposure</brief_title>
	<detailed_description>DESIGN HIV-1 infected subject CD4 nadir &gt; 200 cells/mm3 , history virologic failure plasma HIV RNA &lt; 50 copies/mL least 48 week United States Department Health Human Services ( DHHS ) recommend alternative three-drug antiretroviral regimen randomize dolutegravir ( DTG ) plus lamivudine ( Arm 1 ) continuation current regimen ( Arm 2 ) 48 week . The primary endpoint virologic failure define confirmed plasma HIV-1 RNA &gt; 50 copies/mL Week 24 All subject undergo routine monitoring include plasma HIV-1 RNA , CD4/CD8 count , hematology , chemistry fast lipid . Resistance test do patient experience virologic failure . Single-copy HIV-1 assay do quantify residual viremia . DURATION 48 week SAMPLE SIZE 90 subject POPULATION HIV-1-infected men woman , 18 year old , CD4 nadir &gt; 200 cells/mm3 , baseline resistance , history virologic failure , HIV RNA &lt; 50 copies/mL least 48 week prior study entry DHHS recommend alternative three-drug regimen REGIMEN Subjects randomize ( 1:1 ) : Arm 1 : dolutegravir 50 mg plus lamivudine 300 mg daily OR Arm 2 : Continue current DHHS recommend alternative three-drug antiretroviral regimen</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 Infection HIV1 RNA &lt; 50 copies/mL measurement within 48 week prior study entry DHHS recommend alternative threedrug antiretroviral regimen . ( A history switch simplification and/or tolerability allow . At least two measurement within previous 48 week require prior study screen . ) No history virologic failure , define consecutive HIV RNA &gt; 50 copies/mL 12 month initiate ART . An isolated ( nonconsecutive ) HIV RNA &gt; 50 copies/mL ( le 400 copies/mL ) permit 12 month initiate ART 48week window prior study entry . Screening plasma HIV RNA &lt; 20 copies/mL use COBAS AmpliPrep/COBAS TaqMan HIV1 Test V2.0 , obtain within 45 day prior study entry Nadir CD4 count &gt; 200 cells/mm Pretreatment genotype document mutation protease reverse transcriptase gene No know resistance integrase inhibitor Laboratory value obtain within 45 day prior study entry : ANC &gt; 750 Hemoglobin &gt; 10 g/dL Platelets &gt; 50,000 Calculated creatinine clearance ( CrCl ) &gt; 50 mL/min Negative serum urine pregnancy test Men woman age great equal 18 year . Ability continue current regimen ( i.e , uninterrupted access ) No evidence chronic hepatitis B Serious illness AIDSrelated complication within 21 day screen require systemic treatment and/or hospitalization Treatment within 30 day prior study entry immune modulators Vaccination within 7 day Active HCV treatment anticipate need treatment within study period . ( HCV infection alone exclusionary ) Unstable liver disease severe hepatic impairment Known allergy hypersensitivity DTG lamivudine . Active drug alcohol use dependence could interfere adherence study requirement ALT ( alanine aminotransferase ) &gt; 5 x ULN ( upper limit normal ) OR ALT &gt; 3 x ULN total bilirubin &gt; 1.5 x ULN ( 35 % direct bilirubin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>